{
  "id": 16715730,
  "title": "Merck's KEYTRUDA Cuts Progression Risk By 43% In Phase 3 Endometrial Cancer Trial",
  "url": "https://urgent.news/2026/10/27/mercks-keytruda-cuts-progression-risk-by-43-in-phase-3-endometrial",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-27T04:44:20.000Z",
  "source": {
    "name": "Nasdaq Markets",
    "slug": "nasdaq-markets",
    "url": "https://www.nasdaq.com/articles/mercks-keytruda-cuts-progression-risk-43-phase-3-endometrial-cancer-trial"
  },
  "original_language": "en",
  "account": null,
  "summary": "(RTTNews) - Merck & Co., Inc. (MRK) announced positive results from the Phase 3 KEYNOTE-C93 trial, evaluating KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, as monotherapy for the treatment of patients with mismatch repair deficient (dMMR) advanced or recurrent endometrial",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}